Determination of the spatiotemporal dependence of Pseudomonas aeruginosa biofilm viability after treatment with NLC-colistin

International Journal of Nanomedicine

Volumn 12, Issue , 2017, Pages 4409-4413

  Sans Serramitjana, Eulalia ^a   Jorba, Marta ^a   Pedraz, José Luis ^b   Vinuesa, Teresa ^a   Viñas, Miguel ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Anti biofilm activity; Colistin sulfate; Confocal laser scanning microscopy; Cystic fibrosis; Lipid nanoparticles; P. aeruginosa

Indexed keywords

COLISTIN; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; DRUG CARRIER; LIPID; NANOMATERIAL;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIABILITY; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BIOFILM; CONFOCAL LASER SCANNING MICROSCOPY; CONTROLLED STUDY; NANOENCAPSULATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; CHEMISTRY; CYSTIC FIBROSIS; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SPATIOTEMPORAL ANALYSIS;

ANTI-BACTERIAL AGENTS; BIOFILMS; COLISTIN; CYSTIC FIBROSIS; DRUG CARRIERS; HUMANS; LIPIDS; MICROBIAL SENSITIVITY TESTS; NANOSTRUCTURES; PSEUDOMONAS AERUGINOSA; SPATIO-TEMPORAL ANALYSIS;

EID: 85020934671     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S138763     Document Type: Article

References (29)

1. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis lung infections associated with cystic fibrosis. Clin Microbiol Rev. 2002;15(2):194–222.
2. Drenkard E, Ausubel FM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature. 2002;416(6882):740–743.
3. Machineni L, Rajapantul A, Nandamuri V, et al. Influence of nutrient availability and quorum sensing on the formation of metabolically inactive microcolonies within structurally heterogeneous bacterial biofilms: an individual-based 3D cellular automata model. Bull Math Biol. 2017;79(3):594–618.
4. Taylor PK, Yeung AT, Hancock RE. Antibiotic resistance in Pseudomonas aeruginosa biofilms: towards the development of novel anti-biofilm therapies. J Biotechnol. 2014;191:121–130.
5. Hancock REW, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol. 2006;24(12):1551–1557.
6. Hancock RE. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis. 2001;1(3):156–164.
7. Haney EF, Mansour SC, Hancock RE. Antimicrobial peptides: an introduction. Methods Mol Biol. 2017;1548:3–22.
8. Li J, Nation RL, Milne RW, et al. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents. 2005;25(1):11–25.
9. Döring G, Flume P, Heijerman H, Elborn JS; Consensus Study Group. Treatment of lung infection in patients with cystic fibrosis: Current and future strategies. J Cyst Fibros. 2012;11(6):461–479.
10. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: Results from the SENTRY antimicrobial surveillance program (2006–2009). J Antimicrob Chemother. 2011;66(9):2070–2074.
11. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999;43(6):1379–1382.
12. Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161–168.
13. Jeannot K, Bolard A, Plésiat P. Resistance to polymyxins in Gram-negative organisms. Int J Antimicrob Agents. 2017;49(5): 526–535.
14. Cipolla D, Shekunov B, Blanchard J, Hickey A. Lipid-based carriers for pulmonary products: Preclinical development and case studies in humans. Adv Drug Deliv Rev. 2014;75:53–80.
15. Pelgrift RY, Friedman AJ. Nanotechnology as a therapeutic tool to combat microbial resistance. Adv Drug Deliv Rev. 2013;65(13–14):1803–1815.
16. Sans-Serramitjana E, Fusté E, Martínez-Garriga B, et al. Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients. J Cyst Fibros. 2016;15(5):611–618.
17. Pamp SJ, Gjermansen M, Johansen HK, Tolker-Nielsen T. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol Microbiol. 2008;68(1):223–240.
18. Pastor M, Moreno-sastre M, Esquisabel A, et al. Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis. Int J Pharm. 2014;477(1–2):485–494.
19. Singh R, Monnappa AK, Hong S, Mitchell RJ, Jang J. Effects of carbon dioxide aerosols on the viability of Escherichia coli during biofilm dispersal. Sci Rep. 2015;5:13766.
20. Klodzińska SN, Priemel PA, Rades T, et al. Inhalable antimicrobials for treatment of bacterial biofilm-associated sinusitis in cystic fibrosis patients: challenges and drug delivery approaches. Int J Mol Sci. 2016;17(10). pii: E1688.
21. Nafee N, Husari A, Maurer CK, et al. Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors. J Control Release. 2014;192:131–140.
22. Islan GA, Tornello PC, Abraham GA, et al. Smart lipid nanoparticles containing levofloxacin and DNase for lung delivery. Design and characterization. Colloids Surfaces B Biointerfaces. 2016;143:168–176.
23. Moormeier DE, Bayles KW. Staphylococcus aureus biofilm: a complex developmental organism. Mol Microbiol. 2017;104(3):365–376.
24. Yang L, Nilsson M, Gjermansen M, Givskov M, Tolker-Nielsen T. Pyoverdine and PQS mediated subpopulation interactions involved in Pseudomonas aeruginosa biofilm formation. Mol Microbiol. 2009;74(6):1380–1392.
25. Flemming HC, Wingender J, Szewzyk U, Steinberg P, Rice SA, Kjelleberg S. Biofilms: an emergent form of bacterial life. Nat Rev Microbiol. 2016;14(9):563–575.
26. Rollet C, Gal L, Guzzo J. Biofilm-detached cells, a transition from a sessile to a planktonic phenotype: a comparative study of adhesion and physiological characteristics in Pseudomonas aeruginosa. FEMS Microbiol Lett. 2009;290(2):135–142.
27. Kim J, Hahn JS, Franklin MJ, Stewart PS, Yoon J. Tolerance of dormant and active cells in Pseudomonas aeruginosa PA01 biofilm to antimicrobial agents. J Antimicrob Chemother. 2009;63(1):129–135.
28. Bjarnsholt T, Ciofu O, Molin S, Givskov M, Høiby N. Applying insights from biofilm biology to drug development – can a new approach be developed? Nat Rev Drug Discov. 2013;12(10):791–808.
29. Haagensen JAJ, Klausen M, Ernst RK, et al. Differentiation and distribution of colistin- and sodium dodecyl sulfate-tolerant cells in Pseudomonas aeruginosa biofilms. J Bacteriol. 2007;189(1):28–37.